{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE292nnn/GSE292718/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Genomics"],"species":["Homo sapiens"],"gds_type":["Genome binding/occupancy profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292718"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Super-enhancers-driven SOX4/SMAD3 enhances AXL signaling via membrane phospholipid remodeling to accelerate leukemia progression [CUT&Tag]","description":"Cancer often involves aberrant epigenetic activation. In CML-BP, super - enhancer - driven SOX4 and SMAD3 form an auto - regulatory axis. They co - regulate epigenome, activate AXL - related pathways, and mediate membrane phospholipid remodeling. Bemcentinib, an AXL inhibitor, can inhibit CML - BP progression. SOX4/SMAD3 are key factors and Bemcentinib a potential therapy.","dates":{"publication":"2026/05/15"},"accession":"GSE292718","cross_references":{"GSM":["GSM9034441","GSM8864151","GSM8864141","GSM8864152","GSM8864150","GSM9034440","GSM8864148","GSM8864149","GSM8864146","GSM8864147","GSM8864144","GSM8864145","GSM8864153","GSM8864142","GSM8864154","GSM8864143"],"GPL":["34284"],"GSE":["292718"],"taxon":["Homo sapiens"],"PMID":["[41721601]"]}}